Another investigation showed that exosomal H19 promoted resistance to erlotinib in NSCLC through the regulation of miR-615-3p/ATG7 axis which may offer a prospective diagnosis and treatment marker for NSCLC patients (Pan and Zhou, 2020). This evidence concerns the gene H19 and non-small cell lung carcinoma.